India markets open in 3 hours 21 minutes
  • BSE SENSEX

    48,732.55
    +41.75 (+0.09%)
     
  • Nifty 50

    14,677.80
    -18.70 (-0.13%)
     
  • Dow

    34,382.13
    +360.73 (+1.06%)
     
  • Nasdaq

    13,429.98
    +304.98 (+2.32%)
     
  • BTC-INR

    3,372,671.25
    -102,262.50 (-2.94%)
     
  • CMC Crypto 200

    1,278.61
    -79.95 (-5.88%)
     
  • Hang Seng

    28,027.57
    +308.87 (+1.11%)
     
  • Nikkei

    28,178.35
    +93.88 (+0.33%)
     
  • EUR/INR

    88.9784
    +0.0025 (+0.00%)
     
  • GBP/INR

    103.2201
    -0.0036 (-0.00%)
     
  • AED/INR

    19.8930
    0.0000 (0.00%)
     
  • INR/JPY

    1.4906
    +0.0003 (+0.02%)
     
  • SGD/INR

    54.9720
    +0.0060 (+0.01%)
     

Alembic Pharma gets USFDA approval for depression treatment drug

·1-min read

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Sinequan capsules of Pfizer Inc. The drug is is used to treat mental/mood problems such as depression and anxiety.

The capsules have an estimated market size of $41 million for twelve months ending December 2020 according to IQVIA.

Alembic has a cumulative total of 141 ANDA approvals (124 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

The drug maker reported 13.8% jump in consolidated net profit to Rs 259.20 crore on a 8.7% rise in net sales to Rs 1,314.33 crore in Q3 FY21 over Q3 FY20.

The Alembic Pharma scrip was up 0.29% to Rs 1006.65 on the BSE.



Source: Capitalmarket.com